Skip to main content
. 2010 Oct 7;15(10):1063–1072. doi: 10.1634/theoncologist.2010-0033

Figure 1.

Figure 1.

Bar graphs showing the effects of the MBL2-promoter −550H/L polymorphism (A), MBL2-promoter −221X/Y polymorphism (B), and MBL2-promoter phenotypes (high, HY/HY and HY/LY; medium, LY/LY and HY/LX; and low, LY/LX and LX/LX) in patients with the wild-type exon polymorphism (A/A) (C) on the incidence of febrile neutropenia in cancer patients treated with irinotecan.